Nanoparticle formulated alpha-galactosylceramide activates NKT cells without inducing anergy

Vaccine

Volumn 27, Issue 25-26, 2009, Pages 3484-3488

  Thapa, Prakash ^a   Zhang, Guodong ^a   Xia, Chengfeng ^b   Gelbard, Alexander ^a   Overwijk, Willem W ^a   Liu, Chengwen ^a   Hwu, Patrick ^a   Chang, David Z ^a   Courtney, Amy ^a   Sastry, Jagannadha K ^a   Wang, Peng G ^b   Li, Chun ^a   Zhou, Dapeng ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

alpha galactosylceramide; Biodegradable nanoparticle; Dendritic cells; Natural killer T cells; Phagocytosis; T cell anergy

Indexed keywords

ALPHA GALACTOSYLCERAMIDE; CD11B ANTIGEN; CD45 ANTIGEN; GLYCOPROTEIN P 15095; NANOPARTICLE; POLYLACTIC ACID;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; B LYMPHOCYTE; CELL ACTIVATION; CELL POPULATION; CELL STIMULATION; CLONAL ANERGY; CONTROLLED STUDY; DENDRITIC CELL; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG FORMULATION; DRUG RELEASE; IN VITRO STUDY; IN VIVO CULTURE; MACROPHAGE; MOUSE; NATURAL KILLER T CELL; NONHUMAN; PRIORITY JOURNAL;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; CHEMISTRY, PHARMACEUTICAL; DENDRITIC CELLS; GALACTOSYLCERAMIDES; IMMUNE TOLERANCE; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED C57BL; NANOPARTICLES; NATURAL KILLER T-CELLS;

EID: 67349171859     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.01.047     Document Type: Article

References (24)

1. Kobayashi E., Motoki K., Uchida T., Fukushima H., and Koezuka Y. KRN7000, a novel immunomodulator, and its antitumor activities. Oncol Res 7 10-11 (1995) 529-534
2. Kawano T., Cui J., Koezuka Y., Toura I., Kaneko Y., Motoki K., et al. TCR-mediated activation of valpha14 NKT cells by glycosylceramides. Science 278 November (5343) (1997) 1626-1629
3. Fujii S., Shimizu K., Smith C., Bonifaz L., and Steinman R.M. Activation of natural killer T cells by alpha-galactosylceramide rapidly induces the full maturation of dendritic cells in vivo and thereby acts as an adjuvant for combined CD4 and CD8 T cell immunity to a coadministered protein. J Exp Med 198 July (2) (2003) 267-279
4. Zhou D. OX40 signaling directly triggers the antitumor effects of NKT cells. J Clin Invest 11 November (117) (2007) 3169-3172
5. Choi Y.S., Hoory T., Monie A., Wu A., Connolly D., and Hung C.F. alpha-Galactosylceramide enhances the protective and therapeutic effects of tumor cell based vaccines for ovarian tumors. Vaccine 26 October (46) (2008) 5855-5863 Epub 2008 Sep 2
6. Huang Y., Chen A., Li X., Chen Z., Zhang W., Song Y., et al. Enhancement of HIV DNA vaccine immunogenicity by the NKT cell ligand, alpha-galactosylceramide. Vaccine 26 March (15) (2008) 1807-1816 Epub 2008 Feb 20
7. Ko S.Y., Lee K.A., Youn H.J., Kim Y.J., Ko H.J., Heo T.H., et al. Mediastinal lymph node CD8alpha-DC initiate antigen presentation following intranasal coadministration of alpha-GalCer. Eur J Immunol 37 August (8) (2007) 2127-2137
8. Youn H.J., Ko S.Y., Lee K.A., Ko H.J., Lee Y.S., Fujihashi K., et al. A single intranasal immunization with inactivated influenza virus and alpha-galactosylceramide induces long-term protective immunity without redirecting antigen to the central nervous system. Vaccine 25 July (28) (2007) 5189-5198 Epub 2007 May 21
9. Galli G., Pittoni P., Tonti E., Malzone C., Uematsu Y., Tortoli M., et al. Invariant NKT cells sustain specific B cell responses and memory. Proc Natl Acad Sci USA 104 March (10) (2007) 3984-3989 Epub 2007 Feb 27
10. Ko S.Y., Ko H.J., Chang W.S., Park S.H., Kweon M.N., and Kang C.Y. alpha-Galactosylceramide can act as a nasal vaccine adjuvant inducing protective immune responses against viral infection and tumor. J Immunol 175 September (5) (2005) 3309-3317
11. Silk J.D., Hermans I.F., Gileadi U., Chong T.W., Shepherd D., Salio M., et al. Utilizing the adjuvant properties of CD1d-dependent NK T cells in T cell-mediated immunotherapy. J Clin Invest 114 December (12) (2004) 1800-1811
12. Gonzalez-Aseguinolaza G., Van Kaer L., Bergmann C.C., Wilson J.M., Schmieg J., Kronenberg M., et al. Natural killer T cell ligand alpha-galactosylceramide enhances protective immunity induced by malaria vaccines. J Exp Med 195 March (5) (2002) 617-624
13. Fujii S., Shimizu K., Kronenberg M., and Steinman R.M. Prolonged IFN-gamma-producing NKT response induced with alpha-galactosylceramide-loaded DCs. Nat Immunol 3 September 9 (2002) 867-874 Epub 2002 Aug 5
14. Uldrich A.P., Crowe N.Y., Kyparissoudis K., Pellicci D.G., Zhan Y., Lew A.M., et al. NKT cell stimulation with glycolipid antigen in vivo: costimulation-dependent expansion, Bim-dependent contraction, and hyporesponsiveness to further antigenic challenge. J Immunol 5 September (175) (2005) 3092-3101
15. Parekh V.V., Wilson M.T., Olivares-Villagómez D., Singh A.K., Wu L., Wang C.R., et al. Glycolipid antigen induces long-term natural killer T cell anergy in mice. J Clin Invest 115 September (9) (2005) 2572-2583
16. Lee P.T., Putnam A., Benlagha K., Teyton L., Gottlieb P.A., and Bendelac A. Testing the NKT cell hypothesis of human IDDM pathogenesis. J Clin Invest 110 September (6) (2002) 793-800
17. Heissmeyer V., Macian F., Im S.H., Varma R., Feske S., Venuprasad K., et al. Calcineurin imposes T cell unresponsiveness through targeted proteolysis of signaling proteins. Nat Immunol 5 March (3) (2004) 255-265 Epub 2004 Feb 15
18. Chang D.H., Osman K., Connolly J., Kukreja A., Krasovsky J., Pack M., et al. Sustained expansion of NKT cells and antigen-specific T cells after injection of alpha-galactosyl-ceramide loaded mature dendritic cells in cancer patients. J Exp Med 201 May (9) (2005) 1503-1517 [Erratum in: J Exp Med 2007;204(October (10)):2487]
19. Zwiorek K., Bourquin C., Battiany J., Winter G., Endres S., Hartmann G., et al. Delivery by cationic gelatin nanoparticles strongly increases the immunostimulatory effects of CpG oligonucleotides. Pharm Res 25 March (3) (2008) 551-562 Epub 2007 Oct 3
20. Reddy S.T., van der Vlies A.J., Simeoni E., Angeli V., Randolph G.J., O'Neil C.P., et al. Exploiting lymphatic transport and complement activation in nanoparticle vaccines. Nat Biotechnol 25 October (10) (2007) 1159-1164 Epub 2007 Sep 16
21. Uto T., Wang X., Sato K., Haraguchi M., Akagi T., Akashi M., et al. Targeting of antigen to dendritic cells with poly(gamma-glutamic acid) nanoparticles induces antigen-specific humoral and cellular immunity. J Immunol 178 March (5) (2007) 2979-2986
22. Zhou D., Mattner J., Cantu III C., Schrantz N., Yin N., Gao Y., et al. Lysosomal glycosphingolipid recognition by NKT cells. Science 306 December (5702) (2004) 1786-1799 Epub 2004 Nov 11
23. Liu Y., Goff R.D., Zhou D., Mattner J., Sullivan B.A., Khurana A., et al. A modified alpha-galactosyl ceramide for staining and stimulating natural killer T cells. J Immunol Methods 312 December (1-2) (2006) 34-39 Epub 2006 Mar 6
24. Overwijk W.W., Theoret M.R., Finkelstein S.E., Surman D.R., de Jong L.A., Vyth-Dreese F.A., et al. Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8 + T cells. J Exp Med 198 August (4) (2003) 569-580